Silexion Therapeutics Corp (SLXN) stock
SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.44−0.21 (-12.73%)
Close on Nov 18, 2026Market cap $868.40KP/E –Yield –
Silexion Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Silexion Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $8.24M, up 77.8% year over year. For fiscal 2025 it was $7.14M, up 22.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.14M | +22.8% |
| FY2024 | Dec 31, 2024 | $5.82M | +56.8% |
| FY2023 | Dec 31, 2023 | $3.71M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.29M | -40.4% |
| Q2 FY2026 | Jun 30, 2026 | $2.21M | +117.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.37M | +132.2% |
| Q4 FY2025 | Dec 31, 2025 | $3.38M | +287.5% |
| Q3 FY2025 | Sep 30, 2025 | $2.16M | -32.9% |
| Q2 FY2025 | Jun 30, 2025 | $1.02M | +32.9% |
| Q1 FY2025 | Mar 31, 2025 | $590.00K | -38.6% |
| Q4 FY2024 | Dec 31, 2024 | $871.00K | -30.7% |
| Q3 FY2024 | Sep 30, 2024 | $3.22M | +501.3% |
| Q2 FY2024 | Jun 30, 2024 | $766.00K | -38.0% |
| Q1 FY2024 | Mar 31, 2024 | $961.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $1.26M | – |
| Q3 FY2023 | Sep 30, 2023 | $535.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $1.24M | – |
See a number that looks wrong?